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University of Vienna, General Hospital Vienna, Austria, EuropeBackground. The role of Chlamydia pneumoniae in the pathogenesis of aortic aneurysm is controversial. We investigated
the presence of C. pneumoniae in tissue samples excised from patients and controls.
Methods. Aortic wall specimens were obtained from 17 patients with acute Stanford type A aortic dissection, 25 patients
with thoracic aortic aneurysms (TAA) and 23 patients with abdominal aortic aneurysms (AAA). Eighty-three tissue
samples of 73 control patients free of aortic disease were obtained either at surgery or autopsy. The presence of Chlamydia
subspecies DNA (sequences specific for all known Chlamydiaceae) and DNA of C. pneumoniae, C. trachomatis and
C. psittaci were assessed by a validated highly sensitive and specific real time polymerase chain reaction (PCR) analysis.
Atherosclerotic risk factors were assessed in all patients.
Results. We failed to detect C. pneumoniae and C. psittaci-DNA in any of the 148 vessel specimens. C. trachomatis-
DNA was detected in 1/65 patients and in none of 83 controls (PZ0.43). Chlamydia subspecies DNA was found in
samples of eight cases and in one control (PZ0.01), however, no significant differences were found between the subgroups
aortic dissection (PZ0.09), TAA (PZ0.99) and AAA (PZ0.15) and respective controls.
Conclusions. C. pneumoniae does not play a clinically relevant role in acute and chronic aortic disease. The impact of
other organisms of the family Chlamydiaceae needs further evaluation.Keywords: Chlamydia pneumoniae; Aortic dissection; Aortic aneurysm; Real time PCR.Introduction
Chlamydia, obligate intracellular Gram-negative bac-
teria, capable of multiplying in vascular endothelial
and mononuclear cells, has been suggested to be
related to the development and progression of aortic
aneurysms.1–3 The processes underlying aortic aneur-
ysm formation are still unknown, however, it is widely
recognized that aortic aneurysms are closely associ-
ated with chronic transmural inflammation and
destruction of connective tissue proteins within the
aortic wall.4,5 Chlamydia infection may initiate and
trigger this vascular inflammatory process thusing author. Hans Domanovits, MD, Department of
edicine, University of Vienna, Medical School, General
Vienna, Waehringer Guertel 18-20, A-1090 Vienna,
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0547 + 06 $35.00/0 q 2004 Elsevier Ltd. All rights reserincreasing the susceptibility to aortic disease. In
particular, Chlamydia lipopolysaccharides and various
outer membrane proteins of these bacteria are recog-
nized by the human humoral immune system and
immune response may induce pathological processes.6
Seroepidemiological studies have demonstrated an
enhanced serological positivity against C. pneumoniae
in patients within different vascular pathologies (e.g.
coronary artery disease, peripheral artery disease,
cerebral vascular disease and abdominal aortic aneur-
ysm (AAA)).7–9 Experimental and clinical interven-
tional studies assessing the possible role of chronic
infection with Chlamydia, however, provided contro-
versial results.10–15 Studies employing polymerase
chain reaction (PCR), to directly identify chlamydial
DNA, have not confirmed the presence of Chlamydia
within vascular pathologies.16,17 As a consequence, the
role of Chlamydia in the development and progressionEur J Vasc Endovasc Surg 28, 547–552 (2004)
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G. Sodeck et al.548of aortic aneurysms is questionable, and the detection
of Chlamydia in vascular tissue may only be
coincidental.
Data on the presence of Chlamydia subspecies in
thoracic aneurysm and dissection are rare, and results
from abdominal aneurysm studies need validation in
independent patient samples. Using a highly sensitive
and specific real time PCR we have assessed the
presence of Chlamydia subspecies in acute and chronic
thoracic and abdominal aortic diseases. We hypoth-
esized that C. pneumoniae and other Chlamydia species,
known as human pathogens, might be more fre-
quently found in tissue samples of patients with aortic
pathologies compared to disease-free controls.MethodsStudy design
We prospectively studied 65 patients and 73 controls.
Aortic wall specimens were obtained from 17 patients
with acute Stanford type A aortic dissection, 25
patients with thoracic aortic aneurysms (TAA) and
23 patients with AAA. Tissue samples of controls, free
of aortic disease, were obtained from the thoracic aorta
in 73 controls. In 63 of them aortic wall specimens were
obtained during surgery for valve replacement and in
ten cases specimens were obtained at autopsy from
thoracic and from the abdominal aorta. The latter
procedures were done with special care but not under
sterile conditions. There was no clinical evidence of a
current infectious disease in any of the patients or
controls.
The study was approved by the local ethics
committee and performed according to the Declara-
tion of Helsinki.Definitions
Aortic aneurysm was diagnosed and classified accord-
ing to the guidelines published by the European
Society of Cardiology.18 Diagnosis was aided with the
use of computed tomography (nZ64), conventional
angiography (nZ73), magnetic resonance imaging
angiography (nZ1), or autopsy (nZ10). Diabetes
mellitus was defined as a HbA1c greater than 6.0%
on admission and was assumed to be present in all
patients on anti-diabetic medication or insulin therapy.
Hyperlipidemia was considered to be present in all
patients receiving lipid lowering therapy or in patients
with fasting total serum cholesterol greater than
200 mg/dl, LDL cholesterol greater than 130 mg/dlEur J Vasc Endovasc Surg Vol 28, November 2004or serum triglycerides greater than 180 mg/dl.
Chronic arterial hypertension was defined as a history
of hypertension with or without chronic intake of
antihypertensive drugs. History of previous vascular
intervention upon the arteries of lower extremities, or
the presence of an ankle brachial index lower than 0.9
were considered as peripheral artery disease. Chronic
renal insufficiency was defined in stable elevation of
creatinine greater than 2 mg/dl, assessed in laboratory
studies prior to admission. Cerebral vascular disease
was defined as a history of ischemic cerebral events
(e.g., transitory ischemic attack, prolonged reversible
ischemic neurologic deficiency or stroke). Concomi-
tant coronary artery disease was excluded or con-
firmed via history of angina or myocardial infarction,
coronary angiography, past history of coronary revas-
cularisation or identification of hemodynamic signifi-
cant atherosclerotic lesions at autopsy. Patients, who
were smoking more than three cigarettes per day, were
considered as active smokers. Patients with diagnosed
or suspected Marfan, Turner or Ehler–Danlos syn-
drome were not included in the study.Patients
All consecutive patients with chronic stable aortic
disease, scheduled for elective aneurysm surgery, as
well as patients with acute aortic dissection or rupture
admitted within a 3 year—period (March 2000–March
2003) to the Department of Emergency Medicine and
Department of Surgery, Division of Cardiothoracic
Surgery and Vascular Surgery, of a tertiary care
university hospital were eligible for study partici-
pation. Control aortic specimens, free of aortic disease,
were obtained from patients with non-rheumatic
aortic valvular disease, undergoing elective aortic
valve replacement, and from 10 individuals without
any aortic disease at routine autopsy within the same
time interval. In all patients, cardiovascular risk
factors and comorbidities were evaluated by medical
chart review. Signs of current infectious disease were
excluded by medical history, clinical examination,
urinary analysis, laboratory studies of inflammatory
markers and radiologic investigations or autopsy
reports, if applicable.Aortic wall sample
Aortic wall specimens were obtained from the
ascending or the infrarenal abdominal aorta in
patients with thoracic or AAA and/or dissection.
Control-specimens, obtained during autopsy, were
collected simultaneously from the thoracic and
Chlamydia Pneumoniae in Aortic Disease 549abdominal aorta. Samples of the ascending aorta from
patients undergoing aortic valve replacement were
obtained either when establishing cardiopulmonary
bypass from the access site of the arterial cannulae or
in fitting aortic valve prostheses into the ascending
aorta.PCR-analysis
Real time PCR was performed as a two-step procedure
with the TaqMan sequence detection system (Applied
Biosystems, Amersham, CA, USA). Detection of
chlamydial DNA was achieved with primers as
described elsewhere.19 Tissue samples were placed in
sterile screw capped vials, transferred to the labora-
tory where they were immediately processed. Samples
were cut into pieces of equal weight (25 mg each)
using sterile scissors and forceps, and distributed into
sterile Eppendorf vials (2 ml size). DNA extraction
was performed using QIAGEN tissue kit (QIAGEN
GmbH, Munich, Germany) and the extract was used
for Real Time PCR (Applied Biosystems, Amersham,
USA). For each sample four reaction tubes were used;
one positive control, one negative control containing
only PCR mix, the tissue sample extract, and the tissue
sample extract spiked with chlamydial DNA (refer-
ence strains, C. pneumonia [EB Wien IV], C. trachomatis
[CH834], C.psittaci [99P0381] were kindly provided by
P. Apfalter and V. Brade) in order to exclude
contamination and inhibitors. For the detection of all
known Chlamydiaceae (further Chlamydia DNA) a
sequence of 130 bp of the 23-rDNA served as target
for the detection.19 For C. pneumoniae a 62 bp sequence
of the 16 S-rDNA was targeted, for C. trachomatis a
85 bp sequence of the cryptic plasmid and for
C. psittaci an 89 bp sequence of the 16–23 S intergenic
spacer region. The lower detection limit was 10 copies
per mililiter.Statistical methods
Continous data are presented as the median and the
interquartile range (IQR, range from the 25th to the
75th percentile). Percentages were determined for
dichotomous variables. Fisher’s Exact Test was
applied for group comparisons. A two-sided p-value
!0.05 was considered to be statistically significant. All
calculations were performed with MS Excel for
Windows 2002 and SPSS (Version 10.0.7, SPSS Inc.,
IL, USA) for Windows.Results
One hundred and forty-eight tissue samples from 138
individuals were included in this study. Cardiovas-
cular comorbidities and atherothrombotic risk factors
were found in a minority of patients suffering from
acute thoracic aortic dissection and aneurysm, and
were frequently observed in patients with AAA
(Table 1).Chlamydia and aortic disease
We analyzed samples of all patients with aortic disease
(nZ65) and controls (nZ83) with respect to the
presence of Chlamydia DNA. C. pneumoniae DNA was
not detectable in any aortic tissue sample (0 of 148),
C. trachomatis DNA was detected in one patient with
aortic disease, but none of the controls (PZ0.43). DNA
sequences of C. psittaci were not detected in any
sample. Chlamydia DNA was found in eight patients
suffering from aortic disease and in one control
(PZ0.01) (Table 2).
Acute thoracic aortic dissection
We failed to detect C. pneumoniae, C.psittaciand
C. trachomatis DNA in all samples of patients suffering
from acute type A aortic dissection (nZ17) and control
samples (nZ73). Chlamydia DNA was found in two of
17 patient samples versus one of 83 samples from the
control group (PZ0.09) (Table 2).
Thoracic aortic aneurysms
DNA of C. pneumoniae, C. trachomatis, C. psittaci and
Chlamydia subspecies was not detectable in specimens
from patients with TAA (nZ25), but DNA of Chlamy-
dia subspecies was found in one specimen of the
control group (PZ0.99) (Table 2).
Abdominal aortic aneurysm
In all samples from patients suffering from AAA
(nZ23) and 10 controls C. pneumoniae DNA was
not detectable. C. trachomatis DNA, however, was
present in one of the 23 patients (PZ0.99) and
Chlamydia DNA in six of 23 patients (PZ0.15), but
in none of the controls (Table 2).Discussion
In our analysis C. pneumoniae DNA could not be
detected in any aortic tissue sample of 65 patients with
thoracic or abdominal aortic disease and 83 control
tissue samples using a high-sensitive and specific,Eur J Vasc Endovasc Surg Vol 28, November 2004
Table 1. Demographics of patients with acute and chronic aortic disease compared to controls
Aortic dissection Thoracic aneurysm Abdominal aneurysm
Diseased
nZ17
Control
nZ73
P-value Diseased
nZ25
Control
nZ73
P-value Diseased
nZ23
Control
nZ10
P-value
Median
age (IQR)
59 (54–68) 72 (65–76) 58 (47–66) 72 (65–76) 67 (52–73) 69 (58–78)
Male sex
(%)
8 (47) 46 (63) 0.35 19 (76) 46 (63) 0.34 23 (100) 4 (40) 0.001
Diabetes
mellitus
(%)
1 (6) 25 (34) 0.04 0 (0) 25 (34) 0.003 3 (13) 6 (60) 0.01
Hyperten-
sion (%)
13 (76) 49 (67) 0.64 20 (80) 49 (67) 0.33 18 (78) 5 (50) 0.22
Hyperlipi-
da¨mia (%)
6 (35) 51 (69) 0.01 8 (32) 51 (69) 0.002 15 (65) 5 (50) 0.66
Smoking
(%)
4 (23) 11 (15) 0.63 5 (20) 11 (15) 0.79 4 (17) 2 (20) 0.75
Coronary
artery dis-
ease (%)
5 (29) 41 (56) 0.08 5 (20) 41 (56) 0.004 10 (43) 5 (50) 0.97
Cerebro-
vascular
disease (%)
1 (6) 11 (15) 0.54 3 (12) 11 (15) 0.96 4 (17) 2 (20) 0.77
Peripherial
artery dis-
ease (%)
1 (6) 15 (20) 0.28 2 (8) 15 (20) 0.26 6 (26) 2 (20) 0.94
Chronic
renal
insuffi-
ciency (%)
2 (12) 7 (10) 0.81 4 (16) 7 (10) 0.61 1 (4) 4 (40) 0.03
Continuous data are presented as the median and the interquartile range (IQR, range from the 25th to the 75th percentile). Percentages are
determined for dichotomous variables.
G. Sodeck et al.550validated Real time PCR method. In a minority of
specimens Chlamydial DNA was detected. This was
significantly more often in samples from patients than
in controls, although certain atherosclerotic risk factors
were more frequently found in the latter. These
findings suggest that Chlamydia does not play a
significant role in aortic disease.
C. pneumoniae, a gram-negative and obligate intra-
cellular bacterium, has been detected in various
pathologies of the vascular system.1,20–22 PrimaryTable 2. Presence of Chlamydial DNA in aortic specimens; comparis
Overall Aortic Dissection
Dis-
eased
nZ65
Control
nZ83
P Dis-
eased
nZ73
Control
nZ73
P
Chlamydia
DNA*
8 1 0.01 2 1 0.09
Chlamydia
pneumoniae
0 0 0.99 0 0 0.99
Chlamydia
trachomatis
1 0 0.43 0 0 0.99
Chlamydia
psittaci
0 0 0.99 0 0 0.99
Detection of chlamydial DNA in 148 aortic wall samples of 138 patients
Chlamydia subspecies DNA was found in samples of eight cases and in
between the subgroups aortic dissection (PZ0.09), TAA (PZ0.99) and
wall specimens were obtained at autopsy, samples of the thoracic and
* Sequences specific for all known Chlamydiaceae.
Eur J Vasc Endovasc Surg Vol 28, November 2004reports suggested a chronic infection with C. pneumo-
niae as a possible trigger mechanism for athero-
sclerosis, and experimental investigations supported
this hypothesis.10 Pharmacological interventions with
specific antibiotic treatment, however, have shown no
beneficial effects on the progression of arthero-
sclerosis. In addition, several recent studies reported
failure to detect C. pneumoniae in atherosclerotic
vascular tissue.14,16 This paradox may be explained
by the fact that early studies were based on theon between patients and controls
Thoracic Aneurysm Abdominal Aneurysm
Dis-
eased
nZ25
Control
nZ73
P Dis-
eased
nZ23
Control
nZ10
P
0 1 0.99 6 0 0.15
0 0 0.99 0 0 0.99
0 0 0.99 1 0 0.99
0 0 0.99 0 0 0.99
. Whereas Chlamydia pneumonia could not be observed in any patient,
one control (PZ0.01), however, no significant differences were found
AAA (PZ0.15) and respective controls. In 10 patients of those aortic
the abdominal site of aorta were analyzed.
Chlamydia Pneumoniae in Aortic Disease 551prevalence of anti-chlamydial antibodies,15 however,
recent studies demonstrated that there is no corre-
lation between antibody levels and the detection of
C. pneumoniae DNA in abdominal aortic tissue.15 In a
recent study we found no association between
serological signs of chlamydial infection and TAAs.23
In contrast we observed in patients with AAA elevated
levels of immunoglobulin against Chlamydia lipopoly-
saccharides, reflecting an unspecific Chlamydia
immunopathogenicity.23
Reports on the prevalence of Chlamydia infection in
thoracic aneurysm and aortic dissection are rare.23,24
Nysstrom-Rosander and colleagues found an infection
rate of 12% among 32 aortic tissue samples of chronic
TAA. Additionally, a high prevalence of serum IgA
antibodies to C. pneumoniae was observed. In the
present study we found no evidence of C. pneumoniae-
infection in acute and chronic aortic disease, indepen-
dent of the vascular location. A lack of sensitivity of
the applied Real time PCR cannot be presumed. The
extraction procedure, the sensitivity and specificity of
the detection method has been validated in controlled
and multicenter studies.25,26 Lindholt and colleagues
speculated that a variation in the prevalence of
C. pneumoniae infection among populations studied
may explain the controversial results.11 No such
evidence, however, currently exists.
Atherosclerosis, aortic aneurysm and aortic dissec-
tion, although associated, do not seem to be identical
diseases: the detection of C. pneumoniae in athero-
sclerotic vascular tissue may be rather coincidental
and may neither reflect the basis of the underlying
process of atherosclerosis17 nor be the cause of
formation of aneurysms or dissections. Nevertheless,
although we could not detect C. pneumoniae, the
presence of Chlamydia substrains was observed in a
rather small percentage of patients. A role for chronic
Chlamydia infection in aortic aneurysm formation,
therefore, cannot be excluded with certainty, and the
impact of Chlamydia subspecies has to be further
investigated.Limitations
We are aware of several limitations of the present
study. Most importantly, we were unable to obtain
serological results and tissue samples simultaneously
from all patients, and the issue of correlation between
anti-Chlamydia anti-bodies and positive DNA find-
ings cannot be addressed with this data. Nevertheless,
our recent findings are in line with a previous
observation from our group with serological data,
suggesting that particularly thoracic aortic disease isnot associated with Chlamydia infection or immuno-
pathogenicity.23 We cannot exclude observation bias
because of the study design chosen. We obtained
tissue pieces from the most atherosclerotic site of the
aorta, where we expected Chlamydia to be present. This
method of selection has been evaluated in various
previous studies, dealing with the issue of Chlamydia
and atherosclerosis. Since, we analyzed a large
number of samples and failed to detect C. pneumoniae,
this form of selection bias might be of minor
importance. However, we cannot exclude with cer-
tainty that if other regions of the tissue would have
been analyzed the results might have been different.Conclusion
In respect to our findings, C. pneumoniae plays no
clinically relevant role in acute and chronic aortic
disease. The impact of other organisms of the family
Chlamydiaceae is unclear and should be further
assessed.Acknowledgements
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